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from major epidemiological studies. Costs of complications were
derived from published sources. From the government payer per-
spective, direct costs of diabetes complications and of SMBG
were projected over patient lifetimes. Outcomes were discounted
at 3% annually. RESULTS: Depending on type of treatment
(diet/exercise, oral medications, or insulin), greater glycemic
control with SMBG improved (discounted) QALE by 0.10 to
0.15 QALYs and increased total costs by €323 to €703 per
patient. The resulting incremental cost-effectiveness ratios
ranged from €3220 to €7276 per QALY gained, and were well
within current willingness-to-pay limits. SMBG was most cost-
effective in the sub-group of patients being treated with oral
antidiabetic medication. CONCLUSIONS: Within the three
treatment regimens examined, the addition of SMBG was asso-
ciated with increased glycemic control and with improved clini-
cal and economic long-term outcomes. The incremental
cost-effectiveness ratios were of magnitudes typically considered
to indicate good value for money within the French health care
setting. Additional comparative studies are needed to further
assess Utilities and other standard outcomes associated with
SMBG in patients with type 2 diabetes.
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GOVENMENT PAYER SETTING
Palmer AJ1, Minshall ME2,Valentine WJ1, Foos V1,Tunis SL2
1IMS, Allschwil, Switzerland, 2IMS, Fishers, IN, USA
OBJECTIVES: Previous studies have shown that for patients
with type 2 diabetes, self monitoring of blood glucose (SMBG)
can improve glycemic control (with HbA1c improvements of
0.3–0.6%, depending on treatment received). This in turn, can
reduce risks of disease complications. Because monitoring sup-
plies can have high acquisition costs, country-speciﬁc evaluations
of SMBG cost-effectiveness are needed. The aim of this analysis
was to estimate, within Germany, the cost-effectiveness of using
SMBG. METHODS: A validated, published model for type 2
diabetes (The CORE Diabetes Model) was used to project
improvements in quality-adjusted life expectancy (QALE), long-
term costs and cost-effectiveness of SMBG. A series of Markov
models simulated the progression of diabetes-related complica-
tions (cardiovascular, neuropathy, renal and eye disease). Tran-
sition probabilities and HbA1c-dependent adjustments came
from major epidemiological studies. Costs of complications were
derived from published sources. From the Government payer
perspective, direct costs of diabetes complications and of SMBG
were projected over patient lifetimes. Outcomes were discounted
at 3% annually. RESULTS: Depending on type of treatment
(diet/exercise, oral medications, or insulin), greater glycemic
control with SMBG improved (discounted) QALE by 0.05 to
0.12 QALYs and increased total costs by €340 to €1227 per
patient. The resulting incremental cost-effectiveness ratios
ranged from €7558 to €10,447 per QALY gained, and were well
within current willingness-to-pay limits. SMBG was most cost-
effective in the sub-group of patients being treated through diet
and exercise. CONCLUSIONS: Within the three treatment reg-
imens examined, the addition of SMBG was associated with
increased glycemic control and with improved clinical and eco-
nomic long-term outcomes. The incremental cost-effectiveness
ratios were of magnitudes typically considered to indicate good
value for money within the German health service setting. Addi-
tional comparative studies are needed to further assess Utilities
and other standard outcomes associated with SMBG in patients
with type 2 diabetes.
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OBJECTIVES: To project the long-term clinical and cost out-
comes of the addition of acarbose to existing treatments for type
2 diabetes patients in German, Spanish and Taiwanese settings.
METHODS: Patient characteristics and acarbose treatment
effects were based on clinical data from the MERIA meta-analy-
sis. A published computer simulation model of diabetes was used
to project long-term clinical and cost outcomes in patients receiv-
ing acarbose or placebo in addition to their existing treatment.
It was used to project the life expectancy (LE), quality-adjusted
life expectancy (QALE), cumulative incidence of diabetic com-
plications and medical costs over the lifetime of the patients.
Costs were calculated from a third-party health care payer per-
spective with unit costs derived from published sources (2004
Euro values). Costs and clinical beneﬁts were discounted at 5%
(Germany) and 3% (Spain, Taiwan) annually. RESULTS: Long-
term projections indicated acarbose was associated with notable
improvements in LE and QALE compared to placebo. For
Germany, Spain and Taiwan incremental quality-adjusted life
expectancy for acarbose compared to placebo were 0.21, 0.23
and 0.27 QALYs, respectively. Incremental cost (direct medical
costs over patients’ lifetimes) values of €134, €468 and €331
were estimated for the same three country settings. These values
produced incremental cost-effectiveness ratios (ICERs) of €692
(Germany), €2199 (Spain), and €1291 (Taiwan) per QALY
gained for acarbose versus placebo. The additional pharmacy
costs associated with acarbose treatment were largely offset by
reduced complication costs over patients’ lifetimes. Acceptabil-
ity curve analysis showed that with a willingness-to-pay of
€20,000 per QALY gained, the probability of being cost-
effective was 95% in Germany, 93.5% in Spain and 96% in
Taiwan for acarbose versus placebo. CONCLUSIONS: Acarbose
was associated with reduced incidence of diabetes-related com-
plications and improvements in LE and QALE and provides
excellent value for money versus placebo over patients’ lifetimes
in the German, Spanish and Taiwanese settings.
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OBJECTIVES: Type 2 diabetes poses signiﬁcant clinical and eco-
nomic burden to health care systems. It is therefore important to
project economic and quality-adjusted effects of real-life clinical
outcome improvements with different treatment options. This
study aimed to evaluate such impacts when transferring type 2
patients on insulin glargine to insulin detemir. METHODS: Base-
line and 3-month treatment effect data were collected from a
subgroup of 260 patients with type 2 diabetes replacing insulin
glargine with insulin detemir from a prospective, internationally-
based observational trial. Baseline demographic data were: male
46.9%; mean age 63.7 years; duration of diabetes 9.9 years;
HbA1C 7.83%; BMI 30.2 kg/m2. A validated simulation model
of diabetes calculated gains in life years (LYG), quality-adjusted
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life expectancy (QALE), cumulative complication incidences and
total management costs (drug costs plus complications) over 10
years. The model combined a series of interdependent time- and
state-based Markov sub-models of diabetes-related complica-
tions, incorporating 2nd order Monte-Carlo simulation. Future
outcomes were discounted at 3% per annum (US Medicare per-
spective). Sensitivity analyses were performed. RESULTS: At
follow-up, HbA1C was reduced 0.59% from baseline, fasting
blood glucose (FBG) was more tightly controlled (−25 mg/dL),
with mean weight loss of 0.78 kg. Daily dose remained stable
upon replacing glargine (27.3 U vs. 23.8 U). Rate of all hypo-
glycaemia decreased by 728 events per 100 patient years from
baseline, with major and nocturnal reduced by 26 and 208
events/100 patient years, respectively. Long-term projections
indicated these clinical beneﬁts increased LYG (0.07 years) and
QALE (0.31 years). Direct medical costs were $2020 less 
per patient (10 years), largely due to reduced incidence rates 
of complications, predominantly renal and cardiovascular.
CONCLUSION: Patients with type 2 diabetes may experience
clinical outcome beneﬁts when using insulin detemir compared
to glargine. These beneﬁts were projected to reduce treatment
costs and increase QALE through a reduction of diabetes-related
complications.
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OBJECTIVES: Evidence-based measures are necessary in
medical decision-making when comparing modern therapy
options with long-established treatments. As such, data from
naturalistic settings provide important insight to use of such
treatments in actual clinical practice. This study aimed to project
real-life economic and clinical implications of converting type 2
diabetes patients on NPH basal-oral therapy to insulin detemir.
METHODS: Pre-transfer, baseline and end-of-study data for 251
subjects converting from NPH ± orals to detemir ± orals were
analyzed. Patients were an enrolled subgroup of a multi-national,
prospective observational trial (51% male; mean age 61.5 years;
diabetes duration 9 years; HbA1c 7.8%; BMI 30.9 kg/m2). Total
treatment costs (annual drug plus complications), life years
gained (LYG), quality-adjusted life expectancy (QALE), and
cumulative complication incidences were assessed using a vali-
dated model of diabetes-related complications. Fifteen intercon-
nected Markov sub-models employed second order Monte Carlo
simulation and non-parametric bootstrapping (1000 × 1000) to
estimate long-term outcomes (10 year horizon; US Medicare per-
spective), discounted at 3% per annum. Sensitivity analyses were
performed. RESULTS: At 12 weeks post-transfer, mean absolute
HbA1c was reduced 0.58%, with improved fasting blood
glucose (−28 mg/dL) and weight reduction (0.87 kg). Observa-
tion period daily dose did not differ considerably to pre-transfer
NPH (27.8 U vs. 25.7 U). Use of orals remained similar upon
conversion. A reduced rate of all hypoglycaemia (pre- vs. post-
transfer) was observed (−663 events/100 patient years), as were
major and nocturnal episodes (39 and 429 events/100 patient
years, respectively). Clinical beneﬁts led to projected increases in
LYG (0.07 years) and QALE (0.30 years), with associated total
management costs reduced $2416 per patient, primarily from
reductions in major hypoglycaemia and complication risks
(notably ocular and cardiovascular). CONCLUSION: Improved
glycaemic control and reduced hypoglycaemia were observed 
in patients with type 2 diabetes transferring from NPH-based
therapy to detemir, generating projected improvements in
quality-adjusted life expectancy and total costs.
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OBJECTIVES: Many patients with type 2 diabetes are not
achieving recommended HbA1c targets. Barriers preventing the
initiation of more efﬁcacious therapies include economic restric-
tions. The present analysis aimed to evaluate potential clinical
and economic outcomes of initiating insulin detemir among type
2 diabetes patients previously on oral medication alone.
METHODS: Data were analyzed from 1321 patients who par-
ticipated in a 12-week prospective observational trial (50.6%
male; mean age 62.2 years; diabetes duration 6.5 years; HbA1c
8.49%; BMI 29.5 kg/m2). A published and validated simulation
model of diabetes projected total treatment costs (annual drug
plus complications), life years gained (LYG), quality-adjusted life
expectancy (QALE), and complication incidences for patients
commencing detemir versus those modelled to remain insulin
naïve (10 year horizon). The model structure combines 15 inter-
dependent Markov sub-models, simulating the progression of
diabetes-related complications and utilizing second order Monte
Carlo simulation to account statistical uncertainty at the patient
and parameter levels. Outcomes were discounted at 3% per
annum (US Medicare perspective). Sensitivity analyses were 
performed. RESULTS: Initiation of detemir generated a 1.29%
mean reduction in HbA1c over 3 months, with improved fasting
blood glucose (FBG; total (SD): −58 mg/dL (−8.2 mg/dL)), and
no signiﬁcant increase in the occurrence of hypoglycaemia. At
follow-up, 16% of patients discontinued or reduced oral med-
ications. Pharmacoeconomic modelling demonstrated detemir
treatment to improve LYG (0.156 years) and QALE (0.173
years). Reduced major complication incidences were also esti-
mated, including vascular, ocular, and renal events. An incre-
mental cost-effectiveness ratio (ICER) of $657 per QALY gained
was generated. An acceptability curve (willingness-to-pay of
$50,000/QALY) revealed detemir to have a 95.5% chance of
being cost-effective. CONCLUSION: Considerable short-term
clinical beneﬁts were observed among insulin-naïve type 2
patients initiating detemir. Long-term treatment with detemir
was predicted to increase quality-adjusted outcomes and reduce
diabetic complications in a cost-effective manner.
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OBJECTIVES: The US NHANES study reveals that most type 
2 diabetes patients are not achieving endorsed HbA1c goals.
During disease progression, clinicians treating insulin-naïve sub-
jects may optimize continued oral therapy, or prescribe exoge-
nous insulin to induce tighter glycaemic control. The present
analysis aimed to estimate long-term clinical and economic out-
